drugset / Trial / NCT07539441
A Study of Mirdametinib in People With Central Nervous System Tumors
Phase 1/2
Recruiting
26 enrolled
Memorial Sloan Kettering Cancer Center
SpringWorks Therapeutics, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Timeline
- Start
- 2026-04-10
- Primary completion
- 2029-10-10
- Completion
- 2029-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | — | Oral |